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INTRODUCTION  
 
The ultimate goal of medical care is to improve patients’ functional behaviour, both 
physical and psychological. In recent years, the value of quality of life information in 
clinical trials has been widely demonstrated. However, the abundance of health-related 
quality of life (HRQoL) instruments available, each with different units of measurement, 
renders interpretation even more difficult and challenging for clinicians and healthcare 
providers (1). One suggestion for improving the meaningfulness of HRQoL measures in 
clinical practice is the use of the anchor-based technique (2). The Renal Quality of Life 
Profile (RQLP) is a user-friendly self-administered modality independent instrument. Its 
reliability and validity have been demonstrated (3). Basic information about interpretation 
of the scores is not sufficient and when used to signal a change in patient functioning in 
response to a new treatment, the magnitude of the change is often difficult for clinicians 
and healthcare planners to interpret (4). Several different approaches to interpret HRQoL 
score have been used (2). In this study, the anchor-based approach was employed, since it 
is most appropriate for short, relatively simple HRQoL instruments. This approach is based 
on a patient global rating question (GQ) which measures patients’ views of their overall 
impairment of HRQoL due to chronic kidney failure (CKF). The GQ can then be used 
alongside a HRQoL instrument. The use of the anchor-based technique to determine 
categorization for HRQoL measures has been described previously in conjunction with the 
Dermatology Life Quality Index (DLQI) (5), in the Rhinoconjunctivitis Quality of Life 
Questionnaire (RQLQ) (6) and Skindex-29 Questionnaire (7). This methodology will 
facilitate instant interpretation of quality of life scores during consultation and will provide 
support for clinicians to remove apprehension about the use and importance of HRQoL in 
treatment decision-making. The aim of this study was therefore, to assign clinical 
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significance to RQLP scores by establishing ranges of scores or categories within the scale 
of the measure. 
SUBJECTS AND METHODS 
Study design  
This was a prospective study for which a consecutive sample of 260 patients was recruited. 
Data was collected from home and unit haemodialysis, pre-dialysis, peritoneal dialysis and 
transplant outpatient clinics, at the University Hospital of Wales, United Kingdom. 
Patients  
All patients aged 18 years and above diagnosed with chronic renal failure were recruited 
into the study. Patients whose physical condition prevented them from completing the 
questionnaire were excluded. Eligibility of patients for the study was assessed jointly by 
the outpatient clinics coordinator and the respective physician (s). 
Study instruments 
The Renal Quality of Life Profile (RQLP) was used to collect HRQoL data from patients 
with chronic renal failure. It is an original questionnaire based on constructs representing 
renal patient's own quality of life determinants. Two thousand six hundred statements 
related to the quality of life areas most affected by renal conditions were generated from 
patients receiving different treatment modality, nephrologists, renal transplant surgeons and 
renal nurses. The RQLP is a condition specific and modality independent quality of life 
instrument which measures individual perceptions of the impact of disease and treatment 
on patients’ quality of life with different treatment modality (i.e. pre-dialysis, haemodialysis, 
peritoneal dialysis and transplant). The instrument consists of 43 items, with a 5-point Likert 
response scale describing health-related dysfunctional behaviours that are specific to 
chronic renal failure patients and is grouped into five categories [eating and drinking(3 
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items), physical ability (16 items), leisure time (3 items), daily life (13 items)  and impact 
of treatment (8 items)]. The sum of the scores provides a value between 0 (no impact on the 
HRQoL of the patient) and 172 (maximum impact on the HRQoL of the patient). The 
questions are easily understood, with an average completion time of 5-7 minutes (3). The 
RQLP measurement properties have been established and number of studies been carried 
out as part of its developmental work to demonstrate its reliability and sensitivity. The 
reliability of the subscales of the RQLP was tested using Cronbach's alpha, and all showed 
good internal consistency; eating/drinking (α=0.88); physical activities (α=0.90); leisure 
time (α=0.85); psychosocial activities (α=0.84) and impact of treatment (α=0.75) (3). The 
construct validity of the RQLP was explored by comparing the RQLP with the United 
Kingdom Sickness Impact Profile (UKSIP). High correlations were achieved, in particular, 
among the common categories (rs=0.70). The RQLP was compared with SF-36 similarly 
high levels of correlations were achieved in reflecting patients' assessment of their quality 
of life (rs=0.58 to 0.75). The RQLP is also sensitive to deterioration as well as 
improvement (8).Therefore, robustness of the RQLP, a modality independent instrument, 
renders it useful in routine clinical practice. 
 
Anchor-based approach 
There are two main approaches for interpreting HRQoL, the anchor-based and the 
population-based technique. The anchor-based approach (2) used for this study has not 
previously been applied to CKD specific HRQoL instruments; however a similar method 
has been shown to be successful using a dermatology HRQoL measure (5). Our study met 
the two cardinal requirements of this approach (9).  First, the GQ was interpretable and 
understandable by the study subjects. Second, a strong correlation was demonstrated 
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between the target (RQLP) and the anchor (GQ). A global question (GQ) was used in order 
to examine the relationship between patients’ evaluation of their overall HRQoL and the 
multi-dimensional RQLP scores. Following previous studies which have used anchor based 
approach (5) the GQ asks: “Over the past week, how much has your kidney problem 
affected your life?” The five possible response options are: extremely large effect on my 
life (4 points); very large effect on my life (3 points); moderate effect on my life (2 points); 
a small effect on my life (1 point); and no effect on my life (0 points).  
Implementation of quality of life assessment in routine practice and the use of score 
banding system 
 
Quality of life assessment was integrated into the routine process of a renal outpatient 
clinic at the Royal Gwent Hospital, Newport, Wales, United Kingdom.  This involved a 
prospective evaluation of all medical consultations taking place during a fifty-day period 
incorporating the patients’ self-report of quality of life into their routine clinical assessment 
process. At the clinic, patients were asked to complete and score the RQLP in the waiting 
room before seeing the clinicians. The pre-consultation QoL information was passed onto 
the examining clinicians (five in total) and was used during their consultation with the 
patient. The categorization of the RQLP scores was provided at the bottom of the first page 
for ease of interpretation of scores by the clinicians. The clinicians recorded their own 
response with respect to the aspects of the patients’ reported quality of life that they found 
helpful and their influence on change of treatment or new interventions, if any, arising from 
that process. They were also asked to complete three questions in a tick box format 
concerning the value and use of the quality of life information during consultation. 
Statistical analysis  
Data were entered and processed using SPSS version 16 for windows. The Mann-Whitney 
U test was used for gender comparison. The Spearman rank correlation coefficient was 
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used to examine the correlation between the RQLP scores and the GQ scores. The proposed 
“categories” were devised using the mean, median and mode of the GQ scores mapped 
against each RQLP score and the ICC coefficient of agreement was calculated for each set.  
 
RESULTS 
Demographic characteristics of the study participants  
A total of 260 patients with chronic renal failure (haemodialysis n =69, Continuous 
ambulatory peritoneal dialysis (CAPD) n = 65, pre-dialysis n = 57 and transplant n = 69) 
were recruited from the renal outpatient clinics. The patients’ mean age was 58.4 years 
with a median of 59 years and a range of 21 to 90 years. There were 165 (63.5%) male and 
95 (36.5%) female patients. The mean age of males (58.5) was similar to that of the 
females (58.3) despite the wider age range for females (21-90 years) compared to males 
(22-86).  
 
The RQLP scores  
The RQLP scores covered a good range between the minimum score of zero and a 
maximum possible score of 172 with higher score representing more impairment.  The 
overall mean score was 67.2 (SD=41.5) with a median of 61(range=0-169). The mean score 
for males was 60.9 (SD=38.6) with a median of 57 (range=0-158).  For females, HRQoL 
was more impaired with a mean of 78.4 (SD=44) and a median of 73 (range=0-169) 
reflecting a wider range of an 11 score difference. The Mann-Whitney U Test showed a 
significant difference (p<0.01) between men (median=57, n=165) and women (median=73, 
n=95) for the RQLP. 
The GQ scores  
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The patients selected all five possible GQ scores with the middle option i.e. score of 2 
(“moderate effect”) being the most frequently scored, as expected for this type of scale 
(10). The GQ mean scores for males and females were 1.64 and 1.92, respectively. The 
median for both groups was 2 (“moderate effect”). The Mann-Whitney U Test showed no 
significant difference for the GQ scores (p=0.14). The spearman rank correlation 
coefficient showed a strong correlation between the RQLP scores and the GQ scores (r= 
0.73, p< 0.01). 
The development of a categorization system for the RQLP scores  
The RQLP scores and their corresponding GQ scores for all patients were categorised with 
five point intervals, as well as the mean, median and mode of the GQ scores for that 
specific RQLP interval. Subsequently, the RQLP scores were grouped into five categories, 
each corresponding to a level of impairment as indicated by the GQ (Figure 1). There was a 
reasonable amount of overlap between some of the possible discrete categories where a 
number of RQLP scores could have fitted into one of two categories. A number of “grey” 
areas with multiple potential overlap led to a number of different sets of score 
categorizations being produced. The Intraclass Correlation Coefficient (ICC) was then 
calculated to determine the level of agreement between these different groups. Table 1 
shows the different category selections that were proposed with corresponding ICC values 
that were calculated for each set of categories. All the proposed categories had an ICC 
value of 0.8 or greater out of the maximum possible value of 1, which is within the 
acceptable range and indicate strong agreement (11). The proposed RQLP categories of 0-
20, 21-51, 52-93, 94-134, and 135-172 (Set A), showed well balanced data (i.e. the 
majority of the patients fitted within the category that would have been predicted from their 
GQ scores and a very small percentage of patients did not fit within the category that would 
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have been predicted from their GQ scores. This is largely the nature of anchor based 
approach)  (Table 2), whilst sets B, C, D, E, F and G showed problems in the distribution of 
patients along the GQ and the corresponding RQLP scores. The categorization system that 
was therefore proposed for adoption is 0-20 (no effect on patient’ life), 21-51 (small effect 
on patient’s life), 52-93 (moderate effect on patient’s life), 94-134 (very large effect on 
patient’s life) and 135-172 (extremely large effect on patient’s life) (Set A). 
 
Clinicians’ attitude towards the value and use of the RQLP categorization system 
during consultations  
The acceptability and practicality of the RQLP banding scores presented in the previous 
section above was tested in a secondary care renal outpatient clinic. A total of 5 renal 
consultants were recruited into the study who used the RQLP banding system in their 
consultation with 46 patients. The 46 consultations had a response from the doctors 
regarding the use of the RQLP categorization system. Seventy-four percent of the clinicians 
found the categorization of the RQLP helpful in interpreting the scores. Twenty-two 
percent of the consultations reported to have used the RQLP information provided during 
the consultation. Seven percent reported that the RQLP information influenced their 
treatment decision- making. 
 
DISCUSSION 
Health-related quality of life measurement has become increasingly important in clinical 
research, especially for such chronic conditions as kidney disease (12). However, whilst it 
is generally agreed that it is an important area of research, it still remains a difficult concept 
to translate into use in routine clinical practice. Reliability and validity of many of the 
measures used to assess HRQoL in chronic kidney failure has been established using 
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classical test theory. Due to the complexity of many of these measures in both calculation 
of a score and in particular interpreting that score, HRQoL measures have not yet been 
accepted in clinical practice. Therefore, the purpose of this study was to make HRQoL 
scores more meaningful by establishing ranges of scores or categorization within the scale 
of the measure. This approach could provide clinicians with both a rapid overall view of 
the patients’ HRQoL in addition to the detection of small but meaningful changes in 
clinical status over time.  
It was also important that the RQLP and the GQ were closely correlated which was shown 
in this study. Although there was an alternative set of categories that had a higher ICC 
value compared to the proposed category, there are other factors to take into consideration. 
For example, the majority of the patients fitted within the category that would have been 
predicted from their GQ score which made the data set matrix well balanced. A very small 
percentage of patients did not fit within the category that would have been predicted from 
their GQ score. A larger patient population would have given a better range of scores, thus 
eliminating this problem. 
Using a patient’s quality of life information in clinical practice can offer a number of 
benefits leading to optimised treatment decision-making. For example, it can be used to 
prioritise problems, facilitate communication, screen for potential risks, identify 
preferences, monitor changes or response to treatment and train new staff. They can also be 
used in clinical audit and in clinical governance. The first five of these are of immediate 
value in the clinical encounter, while the last three contribute to training, reviewing and 
improving care in the future which in turn contributes to the quality of decision-making 
(13).  Quality of life measures are not a substitute for measuring clinical outcomes 
associated with disease but are an adjunct to them. Being able to interpret the RQLP scores 
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may be helpful to clinicians to detect unrecognized problems, monitor the impact of 
treatment and appreciate patient priorities (14). Overall the provision of HRQoL 
information in clinical practice may facilitate communication, lead to improvements in 
patient’s health status and satisfaction with their care (15). Consequently, this will translate 
into a “patient-centred” clinical practice. 
Using a categorization system will allow harmonisation of treatment strategies between 
clinicians, for example, results from this study show that scores over a value of 93 describe 
patients who are experiencing a poor HRQoL, in other words “those at risk”. For patients 
with a score greater than this value, there would be strong evidence that active intervention 
is required and clinicians will be able to target these patients with appropriate treatment as 
necessary. 
Finally, this approach is not intended to dilute the significance of independent HRQoL 
scores, but instead to provide a complementary process. This will allow healthcare 
professionals to obtain a relatively rapid overall observation of a patient’s HRQoL from the 
categorization in addition to a more thorough examination through the detailed HRQoL 
measure when required. For example, when a patient presents with a score of over 93, 
closer inspection of the HRQoL profile will allow the clinician to identify specific aspects 
of the patient’s life that are most severely affected by the disease, thus allowing a more 
targeted treatment strategy. However, healthcare professionals will be comfortable with 
such scores only when they become familiar with them (16) which will require their routine 
use in clinical research and practice (17). It would however be of interest to clinicians to 
compare the anchor based approach used in this study with linking HRQoL scales such as 
RQLP directly with clinical relevant markers. 
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A larger sample size would have given a more uniform distribution of the RQLP scores. It 
is therefore possible that certain levels of disease severity were not represented in the range 
of scores. The fact that this is a single centre study could be considered as a limitation, 
however, the RQLP is a modality independent instrument and the centre where the patients 
were recruited provides renal services to over two million people living within South 
Wales. 
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Titles and legends  
  
Table 1 Different possible sets of categorization for the Renal Quality of Life scores 
Allocation of RQLP scores into categories  
ICC Bands  0
a 1b 2c 3d 4e 
Set  A 0 - 20 21 - 51 52 - 93 94 -134 135 - 172 0.80 
Set  B 0 - 30 31 - 55 56 - 100 101 -130 131 - 172 0.90 
Set  C 0 - 30 31 - 60 61 - 100 101 -130 131 - 172 0.92 
Set  D 0 - 30 31 - 55 56 - 90 91 - 130 131 - 172 0.94 
Set  E 0 - 27 28 - 54 55 - 95 96 - 122 123 - 172 0.95 
Set  F 0 - 29 30 - 56 57 - 96 97 - 125 126 - 172 0.97 
Set  G 0 - 29 30 - 56 57 - 92 93 - 121 122 to172 0.99 
a No effect on patients' life, b Small effect on patients' life, c Moderate effect on patients' life,  
d Very large effect on patients' life, e Extremely large effect on patients' life 
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Table 2 Distribution of Global Question scores for the proposed Renal 
Quality of Life categories (Set A) 
RQLP categories 
(Scores) 
GQ Score Totals 0a 1b 2c 3d 4e 
Category 0a 
(Scores 0-20) 30 5 0 0 0 35 
Category 1b 
(Scores 21-51) 16 27 21 1 1 66 
Category 2c 
(Scores 52-93) 7 22 36 18 4 87 
Category 3d 
(Scores 94-134) 2 4 15 24 9 54 
Category 4e 
(Scores 135-172) 0 0 1 4 13 18 
Totals 55 58 73 47 27 260 
ICC = 0.80 
a No effect on patients' life, b Small effect on patients' life, c Moderate effect on patients' life,  
d Very large effect on patients' life, e Extremely large effect on patients' life 
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Figure 1 Relationship between the Renal Quality of Life score and the mean, median 
and mode of the global question (GQ) score  
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